| Date | Form | Description | Docs | XBRL | Pages |
| 08/27/13 | ARS | Annual report to security holders |
|
108 | |
| 01/29/13 | 10-K | Annual report pursuant to section 13 and 15(d) |
|
|
244 |
| 01/30/12 | 10-K | Annual report pursuant to section 13 and 15(d) |
|
|
94 |
| 02/14/11 | 10-K | Annual report pursuant to section 13 and 15(d) |
|
102 | |
| 01/31/11 | NT 10-K | Notice under Rule 12b25 of inability to timely file all or part of a Form 10-K, 10-KSB, or 10KT |
|
4 | |
| 06/29/10 | 10-K/A | Annual report pursuant to section 13 and 15(d) |
|
81 | |
| 03/10/10 | 10-K/A | Annual report pursuant to section 13 and 15(d) |
|
80 | |
| 01/29/10 | 10-K | Annual report pursuant to section 13 and 15(d) |
|
121 | |
| 01/16/09 | 10-K | Annual report pursuant to section 13 and 15(d) |
|
59 | |
| 01/15/09 | NT 10-K | Notice under Rule 12b25 of inability to timely file all or part of a Form 10-K, 10-KSB, or 10KT |
|
3 |
Latest News & Events
Anixa Biosciences Announces Abstract Accepted for Presentation at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2019)
Read More...Anixa Biosciences Appoints Dr. Thomas Schlumpberger as Executive Vice President of Diagnostics to Head Liquid Biopsy Development and Commercialization Efforts
Read More...Anixa Biosciences Names Cancer Vaccine Pioneer Dr. Ian H. Frazer to Scientific Advisory Board
Read More...Cancer of the Lung, Breast, Colon, Prostate, and Stomach are the five most prevalent cancers worldwide.